Science:Life Sciences
In this episode, Daphne, Bruce, Tim and guest Jefferies’ Michael Yee discuss the latest happenings in biotech, including recent key earnings, clinical data including ASH abstracts, “BAMG (Bristol Myers Squibb, Amgen, Merck and Gilead) as the new FAANG” and ways that companies are navigating the current challenging financing environment including debt, royalties, reverse mergers & the idea of returning capital after a setback. The episode also delves into the healthy follow-on financing environment.
More Episodes
Episode 77
2023-10-25
2023-10-25
Episode 76
2023-10-16
2023-10-16
Episode 75
2023-10-16
2023-10-16
Episode 74
2023-10-04
2023-10-04
Episode 73
2023-10-03
2023-10-03
Episode 72
2023-09-22
2023-09-22
Episode 71
2023-09-14
2023-09-14
Episode 70
2023-08-29
2023-08-29
Episode 69
2023-08-17
2023-08-17
Episode 68
2023-08-09
2023-08-09
Episode 67
2023-08-01
2023-08-01
Episode 66
2023-08-01
2023-08-01
Episode 65
2023-07-20
2023-07-20
Episode 64
2023-07-03
2023-07-03
Episode 63
2023-06-23
2023-06-23
Episode 62
2023-06-14
2023-06-14
Episode 61
2023-06-06
2023-06-06
Episode 60
2023-05-24
2023-05-24
Episode 59
2023-05-16
2023-05-16
Episode 58
2023-05-02
2023-05-02
Get this podcast on your
phone, FREE
